managing-copd

name	managing-copd
description	Guides COPD management using GOLD classification with inhaler selection and exacerbation prevention. Use when managing COPD, selecting inhalers, or preventing exacerbations.
tags	["management","primary-care"]
metadata	{"author":"casemark","practice_areas":["Family Medicine","Internal Medicine","Primary Care"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing COPD

Guides COPD management using GOLD classification with inhaler selection and exacerbation prevention.

Why This Skill Exists

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, affecting approximately 16 million diagnosed adults with millions more undiagnosed. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 report provides the evidence-based framework for diagnosis, assessment, and treatment, with significant recent updates including the ABE grouping system (replacing ABCD) and emphasis on blood eosinophil-guided therapy. COPD exacerbations drive mortality, cost ($50 billion annually in the U.S.), and progressive lung function decline.

Primary care clinicians manage the majority of COPD patients and are responsible for confirming the diagnosis with spirometry, initiating appropriate inhaler therapy, preventing exacerbations, and coordinating pulmonary rehabilitation. This skill enforces the GOLD-recommended pathway from diagnosis through ongoing management, ensuring that every COPD patient receives guideline-concordant care.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Has COPD been confirmed by post-bronchodilator spirometry (FEV1/FVC <0.70)? Default: verify
2. What is the patient's post-bronchodilator FEV1 % predicted? Default: [REQUIRED]
3. What is the GOLD ABE group assignment (based on symptoms and exacerbation history)? Default: assess
4. What is the mMRC dyspnea score or CAT score? Default: [REQUIRED - either one]
5. What inhalers is the patient currently using (with technique assessment)? Default: per med list
6. How many exacerbations in the past 12 months (moderate = antibiotics/OCS; severe = hospitalization)? Default: [REQUIRED]
7. What is the patient's smoking status and pack-year history? Default: [REQUIRED]
8. Has the blood eosinophil count been checked? Default: pending

Documents to Request

• Post-bronchodilator spirometry report (FEV1, FVC, FEV1/FVC ratio)
• Prior spirometry for trend analysis of FEV1 decline
• Chest imaging (CXR or CT) to exclude alternative diagnoses
• mMRC dyspnea scale or COPD Assessment Test (CAT) questionnaire
• Complete blood count with eosinophil count
• Alpha-1 antitrypsin level (check once in all COPD patients per ATS/ERS)
• Vaccination records
• Pharmacy refill data for inhalers
• Pulmonary rehabilitation referral status
• ED visits and hospitalization records for COPD exacerbations

---

Step 1: Diagnosis Confirmation and Severity Staging

Spirometric diagnosis (REQUIRED—clinical diagnosis alone is insufficient):

• Post-bronchodilator FEV1/FVC <0.70 confirms airflow obstruction
• Consider lower limit of normal (LLN) in patients >70 years to avoid overdiagnosis

GOLD Spirometric Severity:

GOLD Stage	FEV1 % Predicted	Severity
GOLD 1	≥80%	Mild
GOLD 2	50-79%	Moderate
GOLD 3	30-49%	Severe
GOLD 4	<30%	Very severe

GOLD ABE Grouping (2024):

Group	Exacerbation History	Symptoms
A	0-1 moderate exacerbations (no hospitalization)	mMRC 0-1 or CAT <10
B	0-1 moderate exacerbations (no hospitalization)	mMRC ≥2 or CAT ≥10
E (Exacerbator)	≥2 moderate exacerbations OR ≥1 hospitalization	Any symptom level

---

Step 2: Initial Pharmacotherapy by GOLD Group

GOLD Group	Preferred Initial Therapy	Alternative
Group A	Bronchodilator (SABA PRN or SAMA PRN or LABA or LAMA)	Any single bronchodilator based on symptom relief
Group B	LABA + LAMA combination	LABA or LAMA monotherapy if symptoms mild
Group E	LABA + LAMA; if eosinophils ≥300: LABA + LAMA + ICS triple therapy	LABA + ICS if eosinophils ≥300 and no frequent bacterial exacerbations

Key inhaler agents:

Class	Agents	Dosing
LAMA	Tiotropium (Spiriva) 18mcg daily, umeclidinium (Incruse) 62.5mcg daily	Once daily
LABA	Salmeterol 50mcg BID, indacaterol 75mcg daily, olodaterol 2.5mcg daily	Once or twice daily
LABA+LAMA	Umeclidinium/vilanterol (Anoro), tiotropium/olodaterol (Stiolto)	Once daily
ICS+LABA	Fluticasone/salmeterol (Advair), budesonide/formoterol (Symbicort)	Twice daily
Triple (ICS+LABA+LAMA)	Fluticasone furoate/umeclidinium/vilanterol (Trelegy), budesonide/glycopyrrolate/formoterol (Breztri)	Once or twice daily

---

Step 3: Eosinophil-Guided ICS Use

GOLD 2024 recommends eosinophil count to guide ICS decisions in COPD (unlike asthma where ICS is always indicated):

Blood Eosinophils	ICS Recommendation
<100 cells/µL	ICS NOT recommended; low likelihood of benefit; may increase pneumonia risk
100-300 cells/µL	Consider ICS if frequent exacerbations despite LABA+LAMA
≥300 cells/µL	ICS recommended as part of triple therapy (IMPACT, ETHOS trials)

When to withdraw ICS:

• Eosinophils <100 and no exacerbation reduction on ICS
• Recurrent pneumonia episodes on ICS
• ICS was initiated without documented indication
• Taper gradually (do not stop abruptly); ensure LABA+LAMA is in place

---

Step 4: Non-Pharmacologic Management

Intervention	Indication	Evidence
Smoking cessation	ALL current smokers	Most impactful single intervention; slows FEV1 decline (Lung Health Study)
Pulmonary rehabilitation	mMRC ≥2 or after exacerbation	Reduces dyspnea, improves exercise capacity and QOL (Grade A evidence)
Supplemental oxygen	Resting SpO2 ≤88% or PaO2 ≤55 mmHg (or ≤59 with cor pulmonale/polycythemia)	Improves survival per NOTT and MRC trials
NIV (BiPAP)	Chronic hypercapnic respiratory failure (PaCO2 ≥52) stable	Reduces readmission and mortality
Lung volume reduction (surgical or bronchoscopic)	Upper-lobe predominant emphysema with low exercise capacity	Selected patients; pulmonology referral
Vaccinations	ALL COPD patients	Influenza annually; PCV20 (or PCV15+PPSV23); Tdap; Shingrix ≥50; RSV ≥60; COVID-19

Pulmonary rehabilitation prescription:

• Minimum 12 sessions (typically 2-3x/week for 6-12 weeks)
• Includes supervised exercise, breathing techniques, self-management education
• Refer within 4 weeks after hospitalization for exacerbation (reduces readmission by 40%)

---

Step 5: Exacerbation Management and Prevention

Acute exacerbation treatment (ambulatory):

• SABA (albuterol) 4-6 puffs via MDI+spacer q4-6h; or nebulizer 2.5mg q4-6h
• Oral prednisone 40mg daily × 5 days (REDUCE trial: 5 days equivalent to 14 days)
• Antibiotics for 5-7 days if increased sputum purulence: amoxicillin-clavulanate, azithromycin, or doxycycline
• Consider doxycycline or respiratory fluoroquinolone (levofloxacin, moxifloxacin) for complicated exacerbation

Exacerbation prevention strategies:

Strategy	Indication	NNT
Optimized inhaler therapy (LABA+LAMA ± ICS per eos)	All patients with exacerbation history	4-8
Azithromycin 250mg daily prophylaxis	Group E, former smokers, despite optimal inhaler	~3 (MACRO trial); risk: hearing loss, QTc, resistance
Roflumilast 500mcg daily	FEV1 <50%, chronic bronchitis phenotype, ≥2 exacerbations/year	~5; GI side effects, weight loss, psychiatric
Pulmonary rehabilitation	Post-exacerbation	~4 for reducing readmission

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is COPD diagnosis confirmed by post-bronchodilator spirometry (not just clinical)?
2. Is the GOLD ABE group assigned based on current symptoms and exacerbation history?
3. Does the inhaler regimen match the GOLD group with eosinophil-guided ICS decision?
4. Has pulmonary rehabilitation been offered to all symptomatic patients?
5. Is the exacerbation action plan documented with specific medication instructions?

---

Quality Audit

• COPD diagnosis confirmed by post-bronchodilator spirometry (FEV1/FVC <0.70)
• GOLD spirometric severity documented (GOLD 1-4)
• GOLD ABE group assigned with symptom score (mMRC or CAT) and exacerbation count
• Blood eosinophil count checked to guide ICS decision
• Inhaler therapy matches GOLD group recommendation
• Alpha-1 antitrypsin checked at least once
• Inhaler technique assessed and documented at each visit
• Smoking cessation counseling provided and documented (or never smoker)
• Pulmonary rehabilitation referred for patients with mMRC ≥2
• Supplemental oxygen assessed (pulse oximetry at rest; if SpO2 ≤88%, ABG and oxygen prescription)
• Vaccination status current (influenza, pneumococcal, COVID-19, Tdap, Shingrix, RSV)
• Exacerbation action plan provided in writing
• Comorbidities assessed (cardiovascular disease, osteoporosis, depression, lung cancer screening)
• Annual spirometry for FEV1 trend monitoring

---

Guidelines

• Never diagnose COPD without spirometry; clinical symptoms alone overlap with asthma, heart failure, bronchiectasis, and deconditioning
• ICS monotherapy has NO role in COPD (unlike asthma); always pair ICS with LABA at minimum
• Blood eosinophils guide ICS use in COPD: <100 = avoid ICS; ≥300 = add ICS to LABA+LAMA
• SABA overuse (>2 canisters/month) indicates inadequate maintenance therapy and requires step-up
• Alpha-1 antitrypsin deficiency should be tested in ALL patients with COPD regardless of age, ethnicity, or smoking status per ATS/ERS (1-3% of COPD has AAT deficiency)
• Azithromycin prophylaxis must not be started without baseline ECG (QTc assessment), audiometry, and sputum culture for NTM (non-tuberculous mycobacteria)
• Systemic corticosteroids for COPD exacerbations should be limited to 5 days; longer courses increase hyperglycemia, infection, and adrenal suppression without additional benefit
• Refer to pulmonology for GOLD 3-4 severity, frequent exacerbations despite optimal therapy, or suspicion of asthma-COPD overlap (ACO)